gastroenteropancreatic NETs | Clinical Trials Search

1,641 results for “gastroenteropancreatic NETs”

Need more precision?

Filter by phase, recruitment status, country, sponsor, age, and study type.

Refine trial search

Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

22 participants · First posted Jan 11, 2017

Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort

80 participants · First posted Feb 13, 2024

[68 Ga]-DOTANOC PET/CT in GEP-NETs

18 participants · First posted Nov 18, 2015

Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) in Routine Clinical Practice

First posted Mar 29, 2019

Active, not recruiting

Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors

40 participants · First posted Mar 18, 2021

A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

19 participants · First posted May 6, 2022

Active, not recruiting

Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

20 participants · First posted Mar 27, 2019

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

31 participants · First posted Jan 21, 2020

Active, not recruiting

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

29 participants · First posted Feb 11, 2021

Active, not recruiting

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

259 participants · First posted Jun 9, 2021

Page 1 of 71